Small Molecules Targeting Prion Protein Folding Intermediates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying protein folding, such as classical Molecular Dynamics simulations, are limited by the timescales they can simulate, making it difficult to predict the structural transitions of biologically relevant polypeptides larger than 100 amino acids, and existing compounds that block the conformational transition from PrPC to PrPSc do not effectively inhibit prion disease progression.
Innovation Solution
The development of the Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) method, which identifies small organic ligands for the most kinetically and thermodynamically relevant folding intermediate of the prion protein to stabilize and promote degradation of PrP, thereby inhibiting its maturation and replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If classical Molecular Dynamics simulations are used to study protein folding, then the simulation can be performed with available computational methods, but the timescale limitation prevents prediction of structural transitions for biologically relevant polypeptides larger than 100 amino acids
Solution Approach 1:
The patent segments the protein folding process into distinct intermediate states (unfolded, folding intermediate, native) and develops specialized simulation protocols for each stage. This allows the study of large polypeptides by breaking down the complex folding trajectory into manageable segments that can be simulated within computational timescales while maintaining prediction accuracy for structural transitions.
Solution Approach 2:
The patent employs preliminary actions by using enhanced sampling methods and biasing techniques to prepare the simulation system with pre-equilibrated structures and predicted folding pathways before performing production simulations. This allows accurate prediction of structural transitions without requiring excessively long simulation times, as the system is already positioned near the folding transition states.
2Reliability
If existing compounds that block the conformational transition from PrPC to PrPSc are used, then the approach targets the conversion mechanism, but the compounds do not effectively inhibit prion disease progression
Solution Approach 1:
The patent applies preliminary action by targeting and stabilizing the folding intermediate state of PrPC before it converts to the pathogenic PrPSc form. By intervening at this earlier stage in the conformational transition pathway, the compounds prevent the formation of the infectious agent more effectively than compounds that attempt to block the transition from native PrPC to PrPSc, thereby improving inhibition effectiveness against disease progression.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that specifically bind to and stabilize the folding intermediate state of PrPC. These intermediary molecules act as molecular chaperones that prevent the intermediate from progressing to the pathogenic PrPSc conformation, providing a more effective blockade of the disease pathway while maintaining a relatively simple compound structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively suppresses the maturation of PrP into its native conformation, inhibiting PrPSc formation and replication, providing a therapeutic strategy for neurodegenerative disorders, including prion diseases, Alzheimer's, and cancer.
Implementation Method 1
One fundamental process altered by aging is protein folding. When proteins misfold, they acquire alternative, β-sheet rich conformations capable of triggering a cascade of molecular events
Implementation Method 2
these molecules are capable of targeting a folding intermediate of the prion protein (PrPC), thus promoting its degradation from the endoplasmic reticulum through the lysosomal pathway
Data Source
AI summary
Chemical entities are capable of inducing the degradation of the cellular prion protein (PrPC) identified with the pharmacological protein inactivation by folded intermediate targeting (PPI-FIT) methodology.